Integer (NYSE:ITGR) Given New $140.00 Price Target at Truist Financial

Integer (NYSE:ITGR) had its target price lowered by Truist Financial from $163.00 to $140.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price would indicate a potential upside of 20.71% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. Benchmark lifted their price objective on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 21st. KeyCorp upped their target price on shares of Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Raymond James assumed coverage on shares of Integer in a report on Friday, March 28th. They issued an “outperform” rating and a $145.00 price objective for the company. Finally, Oppenheimer lowered shares of Integer from an “outperform” rating to a “market perform” rating in a report on Friday, February 21st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Integer has a consensus rating of “Moderate Buy” and a consensus target price of $146.00.

Integer Stock Up 1.9 %

Shares of NYSE ITGR opened at $115.98 on Friday. Integer has a 1 year low of $104.93 and a 1 year high of $146.36. The stock has a market capitalization of $3.90 billion, a P/E ratio of 34.20, a P/E/G ratio of 1.72 and a beta of 1.09. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The company has a 50-day moving average price of $124.34 and a 200-day moving average price of $131.00.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The firm had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. On average, equities research analysts forecast that Integer will post 6.01 EPS for the current fiscal year.

Institutional Trading of Integer

A number of institutional investors have recently modified their holdings of ITGR. Capital Research Global Investors grew its position in shares of Integer by 16.0% in the 4th quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider’s stock worth $186,960,000 after buying an additional 194,895 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Integer by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 764,528 shares of the medical equipment provider’s stock worth $99,408,000 after purchasing an additional 9,421 shares during the last quarter. Loomis Sayles & Co. L P boosted its stake in Integer by 3.8% in the 4th quarter. Loomis Sayles & Co. L P now owns 558,715 shares of the medical equipment provider’s stock worth $74,041,000 after purchasing an additional 20,688 shares in the last quarter. Congress Asset Management Co. raised its holdings in Integer by 2.0% in the fourth quarter. Congress Asset Management Co. now owns 498,350 shares of the medical equipment provider’s stock worth $66,041,000 after buying an additional 9,565 shares during the last quarter. Finally, Driehaus Capital Management LLC lifted its stake in shares of Integer by 5.5% in the fourth quarter. Driehaus Capital Management LLC now owns 451,464 shares of the medical equipment provider’s stock worth $59,828,000 after buying an additional 23,706 shares in the last quarter. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.